The COVID-19 Prevention Network conducts studies of vaccines and monoclonal antibodies to prevent the spread of the Coronavirus.

The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic by conducting Phase 3 efficacy trials for COVID-19 vaccines and monoclonal antibodies. The CoVPN works to develop and conduct studies to ensure rapid and thorough evaluation of US government-sponsored COVID-19 vaccines and monoclonal antibodies for the prevention and treatment of COVID-19 disease.

Lean more about the specific studies by visiting or call (619) 742-0433.